Skip to main content

Table 4 Associations of SUA concentration with the severity of Steatosis

From: Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study

SUA levels Mild-steatosis Severe-steatosis
  Cases/n (%) OR 95% CI P Cases/n (%) OR 95% CI P
Severity of steatosis (Model 1)
Total (n = 7569)
Q1 72/1419 (5.1) 1    104/1451 (7.2) 1   
Q2 126/1324 (9.5) 2.10 1.55–2.84 < 0.001 212/1410 (15.0) 2.61 2.03–3.34 < 0.001
Q3 180/1228 (14.7) 3.67 2.74–4.92 < 0.001 293/1341 (21.8) 4.81 3.77–6.13 < 0.001
Q4 175/1116 (15.7) 4.16 3.07–5.64 < 0.001 365/1306 (27.9) 7.87 6.16–10.05 < 0.001
Q5 216/1022 (21.1) 6.52 4.78–8.88 < 0.001 486/1292 (37.6) 14.36 11.18–18.46 < 0.001
Men (n = 3126)
Q1 43/548 (7.8) 1    55/560 (9.8) 1   
Q2 77/576 (13.4) 1.76 1.19–2.62 0.005 70/569 (12.3) 1.25 0.86–1.83 0.239
Q3 80/500 (16.0) 2.20 1.48–3.26 < 0.001 117/537 (21.8) 2.51 1.78–3.56 < 0.001
Q4 88/496 (17.7) 2.66 1.80–3.92 < 0.001 133/541 (24.6) 3.14 2.23–4.43 < 0.001
Q5 95/422 (22.5) 3.75 2.54–5.53 < 0.001 209/536 (39.0) 6.44 4.62–8.98 < 0.001
Women (n = 4443)
Q1 31/822 (3.8)     51/842 (6.1)    
Q2 59/788 (7.5) 2.12 1.35–3.31 0.001 93/822 (11.3) 1.99 1.40–2.85 < 0.001
Q3 82/766 (10.7) 3.21 2.09–4.91 < 0.001 144/828 (17.4) 3.31 2.37–4.63 < 0.001
Q4 106/629 (16.9) 5.61 3.69–8.52 < 0.001 249/772 (32.3) 7.57 5.48–10.45 < 0.001
Q5 108/562 (19.2) 6.94 4.55–10.60 < 0.001 339/793 (42.7) 12.06 8.75–16.63 < 0.001
Severity of steatosis (Model 2)
Total (n = 7569)
Q1 72/1419 (5.1) 1    104/1451 (7.2) 1   
Q2 126/1324 (9.5) 1.70 1.24–2.32 0.001 212/1410 (15.0) 1.86 1.39–2.48 < 0.001
Q3 180/1228 (14.7) 2.73 2.01–3.71 < 0.001 293/1341 (21.8) 2.98 2.24–3.96 < 0.001
Q4 175/1116 (15.7) 2.66 1.93–3.67 < 0.001 365/1306 (27.9) 3.71 2.77–4.96 < 0.001
Q5 216/1022 (21.1) 3.48 2.50–4.86 < 0.001 486/1292 (37.6) 5.18 3.83–7.01 < 0.001
Men (n = 3126)
Q1 43/548 (7.8) 1    55/560 (9.8) 1   
Q2 77/576 (13.4) 1.47 0.97–2.22 0.067 70/569 (12.3) 0.95 0.62–1.47 0.815
Q3 80/500 (16.0) 1.67 1.11–2.53 0.015 117/537 (21.8) 1.50 0.99–2.25 0.053
Q4 88/496 (17.7) 1.95 1.30–2.95 0.001 133/541 (24.6) 1.96 1.31–2.93 0.001
Q5 95/422 (22.5) 2.54 1.68–3.84 < 0.001 209/536 (39.0) 2.95 1.99–4.37 < 0.001
Women (n = 4443)
Q1 31/822 (3.8) 1    51/842 (6.1) 1   
Q2 59/788 (7.5) 1.89 1.20–2.98 0.006 93/822 (11.3) 1.58 1.06–2.35 0.025
Q3 82/766 (10.7) 2.42 1.55–3.75 < 0.001 144/828 (17.4) 2.22 1.52–3.24 < 0.001
Q4 106/629 (16.9) 4.02 2.61–6.20 < 0.001 249/772 (32.3) 4.21 2.92–6.05 < 0.001
Q5 108/562 (19.2) 4.17 2.67–6.51 < 0.001 339/793 (42.7) 4.93 3.41–7.12 < 0.001
  1. Category of SUA quintiles
  2. For all participants: Q1, < 231 μmol/L; Q2, 231–271 μmol/L; Q3, 272–312 μmol/L; Q4, 313–366 μmol/L; Q5, ≥ 367 μmol/L
  3. For men: Q1, < 278 μmol/L; Q2, 278–317 μmol/L; Q3, 318–355 μmol/L; Q4, 356–402 μmol/L; Q5, ≥ 403 μmol/L
  4. For women: Q1, < 213 μmol/L; Q2, 213–244 μmol/L; Q3, 245–276 μmol/L; Q4, 277–320 μmol/L; Q5, ≥ 321 μmol/L
  5. Model 1: adjusted for age, sex (only for all participants)
  6. Model 2: adjusted for age, sex (only for all participants), BMI, history of cardiovascular related diseases, DBP, AST, TG, TC, HDL and FPG